L 21649

Drug Profile

L 21649

Alternative Names: L-000021649; L-21649

Latest Information Update: 06 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 06 Mar 2008 No development reported - Phase-I for Acute myeloid leukaemia in USA (unspecified route)
  • 06 Mar 2008 No development reported - Phase-I for Solid tumours in USA (unspecified route)
  • 23 Nov 2005 Phase-I clinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top